Where Will AST SpaceMobile Be In 5 Years?
Ever tried to send a text from the Nevada desert…
Sell
35
ASTH Quote, Financials, Valuation and Earnings
Last price:
$25.7300
Seasonality move
:
28.52%
Day range:
$25.5000 - $26.3000
52-week range:
$23.1200 - $63.2000
Dividend yield:
0%
P/E ratio:
35.76x
P/S ratio:
0.55x
P/B ratio:
1.59x
Volume:
212.7K
Avg. volume:
266.6K
1-year change:
-33.77%
Market cap:
$1.2B
Revenue:
$2B
EPS (TTM):
$0.72
Analysts' Opinion
-
Consensus RatingAstrana Health has received a consensus rating of Buy. The company's average rating is a Buy based on 8 Buy ratings, 3 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $47.8889, Astrana Health has an estimated upside of 85.98% from its current price of $25.7500.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $36.0000 representing 100% downside risk from its current price of $25.7500.
Fair Value
-
According to the consensus of 11 analysts, Astrana Health has 85.98% upside to fair value with a price target of $47.8889 per share.
ASTH vs. S&P 500
-
Over the past 5 trading days, Astrana Health has overperformed the S&P 500 by 2.34% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Astrana Health does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Astrana Health has grown year-over-year revenues for 13 quarters straight. In the most recent quarter Astrana Health reported revenues of $620.4M.
Earnings Growth
-
Astrana Health earnings have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Astrana Health reported earnings per share of $0.14.
Enterprise value:
1.1B
EV / Invested capital:
--
Price / LTM sales:
0.55x
EV / EBIT:
11.25x
EV / Revenue:
0.50x
PEG ratio (5yr expected):
0.78x
EV / Free cash flow:
21.42x
Price / Operating cash flow:
23.85x
Enterprise value / EBITDA:
8.66x
Gross Profit (TTM):
$268.8M
Return On Assets:
2.71%
Net Income Margin (TTM):
1.56%
Return On Equity:
7.09%
Return On Invested Capital:
3.81%
Operating Margin:
3.32%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Income Statement | ||||||
| Revenue | $1.2B | $1.5B | $2.3B | $404.4M | $620.4M | |
| Gross Profit | $204.8M | $241.1M | $268.8M | $74M | $71.3M | |
| Operating Income | $100.4M | $92.4M | $79.8M | $30.1M | $20.6M | |
| EBITDA | $115.3M | $133.4M | $128.9M | $36.7M | $23.8M | |
| Diluted EPS | $0.98 | $1.32 | $0.72 | $0.31 | $0.14 | |
| Period Ending | 2021-03-31 | 2022-03-31 | 2023-03-31 | 2024-03-31 | 2025-03-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $370.3M | $444.4M | $457.7M | $538.8M | $613.3M | |
| Total Assets | $843.3M | $912.3M | $992.6M | $1.2B | $1.3B | |
| Current Liabilities | $126.3M | $160.4M | $165M | $355.3M | $361.3M | |
| Total Liabilities | $378.7M | $380.7M | $414.7M | $773.9M | $813.6M | |
| Total Equity | $464.5M | $531.7M | $577.9M | $452.4M | $517.7M | |
| Total Debt | $239M | $184.6M | $205.6M | $389.2M | $416.4M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $65.8M | $66.5M | $62.8M | $6M | $16.6M | |
| Cash From Investing | -$1.4M | -$122.5M | -$123.8M | -$71M | -$2.4M | |
| Cash From Financing | -$27.7M | $116.9M | -$15.4M | $106.4M | -$44.2M | |
| Free Cash Flow | $45.5M | $52.4M | $52.1M | $5.6M | $13.6M | |
ASTH
Sector
Market Cap
$1.2B
$33.4M
Price % of 52-Week High
40.74%
46.84%
Dividend Yield
0%
0%
Shareholder Yield
-1.67%
-0.6%
1-Year Price Total Return
-33.77%
-37.4%
Beta (5-Year)
0.849
0.632
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
26.84%
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$25.6700
200-day SMA
Sell
Level
$38.9501
Bollinger Bands (100)
Sell
Level
26.7848 - 35.4048
Chaikin Money Flow
Buy
Level
2.1M
20-day SMA
Buy
Level
$25.4430
Relative Strength Index (RSI14)
Sell
Level
43.8002
ADX Line
Sell
Level
28.3819
Williams %R
Neutral
Level
-49.5441
50-day SMA
Sell
Level
$28.7429
MACD (12, 26)
Sell
Level
-0.7730
25-day Aroon Oscillator
Sell
Level
-36
On Balance Volume
Neutral
Level
23.1M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (3.3951)
Buy
CA Score
(Annual)
Level (1.0496)
Sell
Beneish M-Score
(Annual)
Level (-1.0901)
Buy
Momentum Score
Level (4)
Sell
Ohlson Score
Level (0.9077)
Buy
Piotroski F Score
(Annual)
Level (5)
Sell
Quality Ratio Score
Level (4)
Buy
Fundamental Score
Level (6)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Astrana Health Inc is a patient-centered, physician-centric integrated population health management company. The company is working to provide coordinated, outcomes-based medical care cost-effectively. It is focused on physicians providing high-quality medical care, population health management, and care coordination for patients, particularly senior patients and patients with multiple chronic conditions. The company’s three reportable segments are Care Partners, Care Delivery, and Care Enablement. It generates the majority of its revenue from the Care Partners segment.
Stock Forecast FAQ
In the current month, ASTH has received 8 Buy ratings 3 Hold ratings, and 0 Sell ratings. The ASTH average analyst price target in the past 3 months is $47.8889.
-
Where Will Astrana Health Stock Be In 1 Year?
According to analysts, the consensus estimate is that Astrana Health share price will rise to $47.8889 per share over the next 12 months.
-
What Do Analysts Say About Astrana Health?
Analysts are divided on their view about Astrana Health share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Astrana Health is a Sell and believe this share price will drop from its current level to $36.0000.
-
What Is Astrana Health's Price Target?
The price target for Astrana Health over the next 1-year time period is forecast to be $47.8889 according to 11 Wall Street analysts, 8 of them rate the stock a Buy, 0 rate the stock a Sell, and 3 analysts rate the stock a Hold.
-
Is ASTH A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Astrana Health is a Buy. 8 of 11 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of ASTH?
You can purchase shares of Astrana Health via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Astrana Health shares.
-
What Is The Astrana Health Share Price Today?
Astrana Health was last trading at $25.7300 per share. This represents the most recent stock quote for Astrana Health. Yesterday, Astrana Health closed at $25.7500 per share.
-
How To Buy Astrana Health Stock Online?
In order to purchase Astrana Health stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is TTD The Big Winner If Pharma Ads Are Banned?
Last week, Senators Bernie Sanders and Angus King introduced a…
Is Palantir Stock Overvalued?
By every traditional yardstick, including a price‑to‑sales well above 100,…
Stock Ideas
Buy
65
Is MSFT Stock a Buy?
Market Cap: $3.5T
P/E Ratio: 40x
Buy
57
Is NVDA Stock a Buy?
Market Cap: $3.5T
P/E Ratio: 48x
Sell
39
Is AAPL Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 32x
Alerts
Sell
11
VEON alert for Jun 14
VEON [VEON] is down 18.57% over the past day.
Buy
74
DAVE alert for Jun 14
Dave [DAVE] is down 12.68% over the past day.
Buy
54
DAR alert for Jun 14
Darling Ingredients [DAR] is up 9.12% over the past day.
